Matthew J Matasar (Matthew Matasar)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 32

Top Topics

Randomized Controlled Trial

Cardiovascular Risk Factors

Epstein Barr Virus

Hodgkin Lymphoma

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew J Matasar, Menglei Zhu, Ashlee Joseph, Ali Castro, Erin Biggar, Gilles Andre Salles, Andrew D Zelenetz, Gottfried von Keudell
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma. Leukemia & lymphoma (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood advances (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Pier Luigi Luigi Zinzani, Huaqing Wang, Jifeng Feng, Tae Min Kim, Rong Tao, Huilai Zhang, Laura Maria Fogliatto, Clara Maluquer Artigal, Muhit Özcan, Eduardo Patricio Yanez Ruiz, Won Seog Kim, Dmitry Kirtbaya, Iryna Kriachok, Felipe Maciel, Hongwei Xue, Krimo Bouabdallah, Charles Phelps, Shalini Chaturvedi, Anke Weispfenning, Peter N Morcos, Fatuma Catherine Atieno Odongo, Viktoriya Buvaylo, Barrett H Childs, Martin Dreyling, Matthew J Matasar, Paola Ghione
CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood advances (2024)
Pier Luigi Luigi Zinzani, Huaqing Wang, Jifeng Feng, Tae Min Kim, Rong Tao, Huilai Zhang, Laura Maria Fogliatto, Clara Maluquer Artigal, Muhit Özcan, Eduardo Patricio Yanez Ruiz, Won Seog Kim, Dmitry Kirtbaya, Iryna Kriachok, Felipe Maciel, Hongwei Xue, Krimo Bouabdallah, Charles Phelps, Shalini Chaturvedi, Anke Weispfenning, Peter N Morcos, Fatuma Catherine Atieno Odongo, Viktoriya Buvaylo, Barrett H Childs, Martin Dreyling, Matthew J Matasar, Paola Ghione
CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood advances (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood advances (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood advances (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Michael J Buege, Esther Drill, Steven M Horwitz, Andréa LeVoir, Terry Pak, Tim J Peterson, Phuong H Dao, Matthew J Matasar
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. European journal of haematology (2023)
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Yoon Y Cheah, Matthew J Matasar, Gareth Peter Gregory, Dok-Hyun Yoon, Mazyar Shadman, Keith Fay, Sung Soo Yoon, Carlos Panizo, Ian W Flinn, Anna M Johnston, Francesc Bosch, Laurie H Sehn, Michael C Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, L Elizabeth Elizabeth Budde
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood advances (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, Victor Maximov, Andrew G Polson, Katerina Hatzi, Elisabeth A Lasater, Sarit E Assouline, Nancy L Bartlett, L Elizabeth Elizabeth Budde, Matthew J Matasar, Hartmut Koeppen, Emily C Piccione, Deanna Wilson, Michael C Wei, Shen Yin, Elicia Penuel
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Robert N Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin, Steven M Horwitz, Brandon S Imber, Andrew M Intlekofer, William T Johnson, Niloufer Khan, Anita Kumar, Oscar B Lahoud, Jennifer Kimberly Lue, Matthew J Matasar, Alison J Moskowitz, Ariela Noy, Colette N Owens, M Lia Palomba, Heiko Schöder, Santosha A Vardhana, Joachim Yahalom, Andrew D Zelenetz, Gilles Andre Salles, David J Straus
Retrospective Characterization of Nodal Marginal Zone Lymphoma. Blood advances (2023)
William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan, Umut Aypar, Natasha E Lewis, Andrew D Zelenetz, M Lia Palomba, Matthew J Matasar, Ariela Noy, Audrey M Hamilton, Paul A Hamlin, Philip C Caron, David J Straus, Andrew M Intlekofer, Connie Lee Batlevi, Anita Kumar, Colette N Owens, Craig S Sauter, Lorenzo Falchi, Jennifer K Lue, Santosha A Vardhana, Gilles Andre Salles, Ahmet Dogan, Nikolaus D Schultz, Maria E Arcila, Steven M Horwitz
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood advances (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Talya Salz, Emily C Zabor, Peter de Nully Brown, Susanne Oksbjerg Dalton, Nirupa J Raghunathan, Matthew J Matasar, Richard Steingart, Henrik Hjalgrim, Lena Specht, Andrew J Vickers, Kevin C Oeffinger, Christoffer Johansen
Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors. Acta oncologica (Stockholm, Sweden) 61 (9) (2022)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C Piccione, Michael C Wei, Shen Yin, Nancy L Bartlett
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (5) (2021)
Alison J Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santarosa, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Anita Kumar, Oscar B Lahoud, Connie Lee Batlevi, Paul Hamlin, David J Straus, Ildefonso Rodriguez-Rivera, Colette Owens, Philip Caron, Andrew M Intlekofer, Audrey Hamilton, Steven M Horwitz, Lorenzo Falchi, Erel Joffe, William T Johnson, Christina Lee, Maria Lia Palomba, Ariela Noy, Matthew J Matasar, Georgios Pongas, Gilles Andre Salles, Santosha A Vardhana, Beatriz Wills Sanin, Gottfried von Keudell, Joachim Yahalom, Ahmet Dogan, Andrew D Zelenetz, Craig H Moskowitz
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (28) (2021)
Anita Kumar, Carla Casulo, Ranjana H Advani, Elizabeth Budde, Paul M Barr, Connie Lee Batlevi, Philip Caron, Louis S Constine, Savita V Dandapani, Esther Drill, Pamela Drullinsky, Jonathan W Friedberg, Clare Grieve, Audrey Hamilton, Paul A Hamlin, Richard T Hoppe, Steven M Horwitz, Ashlee Joseph, Niloufer Khan, Leana Laraque, Matthew J Matasar, Alison J Moskowitz, Ariela Noy, Maria Lia Palomba, Heiko Schöder, David J Straus, Shreya Vemuri, Joanna Yang, Anas Younes, Andrew D Zelenetz, Joachim Yahalom, Craig H Moskowitz
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (20) (2021)
Lauren E Latella, Madeline Rogers, Howard Leventhal, Patricia A Parker, Steven M Horwitz, Matthew J Matasar, Carma L Bylund, David W Kissane, Kara Franco, Smita C Banerjee
Fear of cancer recurrence in lymphoma survivors: A descriptive study. Journal of psychosocial oncology 38 (3) (2019)
Matthew J Matasar, Stefano Luminari, Paul M Barr, Stefan K Barta, Alexey V Danilov, Brian T Hill, Tycel J Phillips, Mats Jerkeman, Massimo Magagnoli, Loretta J Nastoupil, Daniel O Persky, Jessica Okosun
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. The oncologist 24 (11) (2019)
Sven Borchmann, Erel Joffe, Craig H Moskowitz, Andrew D Zelenetz, Ariela Noy, Carol S Portlock, John F Gerecitano, Connie Lee Batlevi, Philip C Caron, Pamela Drullinsky, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Anita Kumar, Matthew J Matasar, Alison J Moskowitz, Colette N Owens, Maria Lia Palomba, Anas Younes, David J Straus
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood 133 (20) (2019)
Patricia A Parker, Smita C Banerjee, Matthew J Matasar, Carma L Bylund, Madeline Rogers, Kara Franco, Elizabeth Schofield, Yuelin Li, Tomer T Levin, Paul B Jacobsen, Alan B Astrow, Howard Leventhal, Steven Horwitz, David Kissane
Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer 124 (23) (2018)